NCT/Study#
NCT04432207 /
IMU-201-101
An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study Of IMU-201 (PD1-Vaxx), A B-Cell Immunotherapy, In Adults With Non-Small Cell Lung Cancer
DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
